On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD.

 

The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to be substantially completed during the second quarter of 2026.

 

Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs. Fulcrum communicated the workforce reduction on June 4, 2026, and expects that substantially all of these charges will result in future cash expenditures and will be incurred during the second quarter of 2026.

 

The estimates described above are subject to a number of assumptions and actual results may differ materially from the estimates. Fulcrum may also incur additional charges or cash expenditures not currently contemplated due to events that may occur as the restructuring plan is implemented.